MODULATION OF INTRAOCULAR-PRESSURE BY ADENOSINE AGONISTS

被引:28
作者
CROSSON, CE
GRAY, T
机构
[1] Department of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, Texas
来源
JOURNAL OF OCULAR PHARMACOLOGY | 1994年 / 10卷 / 01期
关键词
D O I
10.1089/jop.1994.10.379
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Adenosine receptors have been shown to modulate a variety of physiological functions; however, little is known about the role these receptors play in the modulation of ocular function. To investigate the potential role of adenosine receptors in modulating intraocular pressure (IOP), the A(1) agonist N-6-cyclopentyladenosine (CPA), the nonselective adenosine agonist 5'-N-ethylcarboxamideadenosine (NECA) and the A(2) agonist 8-phenylaminoadenosine (CV-1808) were evaluated. Topical administration of NECA produced a dose-related reduction in IOP. However, an initial ocular hypertension of 1 to 2 hours was also observed in rabbits treated with NECA. The administration of CPA (165 mu g) resulted only in a reduction in IOP, while the administration of CV-1808 produced only an initial ocular hypertension. As adenosine A(1) receptors have been shown to be negatively coupled to adenylate cyclase in several systems, CPA was evaluated for its ability to suppress cAMP formation in the isolated iris/ciliary body. CPA produced a dose-related suppression of cAMP accumulation induced by 10(-6)M forskolin (EC(50) = 3.2 nM). These results indicate that selected adenosine agonists can modulate IOP. The ocular hypotension induced by adenosine agonists is consistent with the activation of adenosine A(1) receptors and may involve the modulation of cAMP levels in the iris/ciliary body.
引用
收藏
页码:379 / 383
页数:5
相关论文
共 16 条
[1]  
Hasslinger C., Catapres (2-[2,6-dichlorophenylamino]-2-imidazoline hydrochloride) -A new drug lowering intraocular pressure, Klin. Mbl. Augenheilk., 154, pp. 95-105, (1969)
[2]  
Mekki Q.A., Turner P., Stimulation of dopamine receptors (type 2) lowers human intraocular pressure, Br. J. Ophthalmol., 69, pp. 909-910, (1985)
[3]  
Liu J.H.K., Neufield A.H., Study of central regulation of intraocular pressure using ventriculocisternal perfusion, Invest. Ophthalmol. Vis. Sci., 26, pp. 136-143, (1985)
[4]  
Burke J.A., Potter D.E., Ocular effects of a relatively selective 0:2 agonist (UK-14,304-18) in cats, rabbits and monkeys, Curr. Eye Res., 5, pp. 665-676, (1986)
[5]  
Crosson C.E., Burke J.A., Chan M.F., Potter D.E., Prejunctional adrenoceptor activity of N-0437: a relatively selective DA2 dopamine receptor agonist Eut, J. Pharmacol., 178, pp. 351-355, (1990)
[6]  
Mittag T.W., Tormay A., Adrenergic receptor subtypes in rabbit iris/ciliary body membranes: classification by radiogand studies, Exp. Eye Res., 40, pp. 239-249, (1985)
[7]  
Crosson C.E., Heath A.R., DeVries G.W., Potter D.E., Pharmacological evidence for heterogeneity of ocular ct2 adrenceptors, Curr. Eye Res., 11, pp. 963-970, (1992)
[8]  
Fredholm B.B., Dunwiddie T.V., How does adenosine inhibit transmitter release, Trends Pharmacol. Sci., 9, (1988)
[9]  
VAN Calker D., Muller M., Hamprecht B., Adenosine regulates via two different types ofreceptors, the accumulation of cyclic AMP in cultured brain cells, J. Neurochem., 33, pp. 999-1005, (1979)
[10]  
Linden J., Structure and function of A1 adenosine receptors, FASEB J., 5, pp. 2668-2676, (1991)